Quick Answer
Cardiff Oncology, Inc. reported Cash and Equivalents of $17.47 million for fiscal year 2025.
Cardiff Oncology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $17.47M | -66.1% |
| 2024 | $51.47M | +137.7% |
| 2023 | $21.66M | +32.5% |
| 2022 | $16.35M | +36.9% |
| 2021 | $11.94M | -90.9% |
| 2020 | $130.98M | +1184.7% |
| 2019 | $10.20M | -11.0% |
| 2018 | $11.45M | +39.2% |
| 2017 | $8.23M | -40.9% |
| 2016 | $13.92M | -79.4% |
| 2015 | $67.49M | +147.3% |
| 2014 | $27.29M | +5.6% |
| 2013 | $25.84M | +138.8% |
| 2012 | $10.82M | +1444.9% |
| 2011 | $700.4K | +1093.1% |
| 2010 | $58.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.13M | -22.3% | -6.0% |
| June 30, 2025 | $10.78M | -57.7% | -55.2% |
| March 31, 2025 | $24.09M | +29.1% | -53.2% |
| December 31, 2024 | $51.47M | +137.7% | +294.8% |
| September 30, 2024 | $13.04M | -14.4% | -48.9% |
| June 30, 2024 | $25.50M | +31.7% | +36.7% |
| March 31, 2024 | $18.66M | +24.2% | -13.8% |
| December 31, 2023 | $21.66M | +32.5% | +42.2% |
- Cardiff Oncology, Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Cardiff Oncology, Inc.’s cash and equivalents has grown by 29660.0% (from $58.7 thousand to $17.47 million).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: